Related Experiment Video

Updated: Dec 31, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Paolo Strati1, Ellen J Schlette2, Luisa M Solis Soto3

  • 1Department of Lymphoma and Myeloma.

Blood
|January 3, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.7K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

493

Related Experiment Videos

Last Updated: Dec 31, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.7K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

493

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

Articles linked to this work by shared authors, journal, and citation graph.

CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Blood neoplasia·2026

Adjunct Hyperbaric Oxygen Therapy for Refractory Infections in Patients with Hematologic Malignancies: A Single-Center Retrospective Study.

Cancers·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Extrauterine mesonephric-like carcinoma: a tumor with a cold lymphocytic immune microenvironment.

Virchows Archiv : an international journal of pathology·2026

Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.

Cancer medicine·2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Blood advances·2026

KPNA2-Mediated MYC Nuclear Import Enhances CAR-T Cell Memory and Potentiates Antitumor Efficacy.

Blood·2026

How I Identify and Diagnose Carriers of Hemophilia and Women and Girls with Hemophilia.

Blood·2026

The origins of rare glycosylphosphatidylinositol-deficient cells in normal and immune-mediated hematopoiesis.

Blood·2026

How I Treat Heavy Menstrual Bleeding in Patients with Bleeding Disorder of Unknown Cause.

Blood·2026

Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.

Blood·2026

A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma.

Blood·2026

From Phase Ib/II to Seamless Phase II/III: A Simulation-Based Discussion of Design Strategies for Dose Optimization and Confirmatory Phase.

Clinical pharmacology and therapeutics·2026

INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis.

Cancer research·2026

Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies.

Journal of comparative effectiveness research·2026

Epidemiology of medication-related problems and antimicrobial utilisation among critically ill cancer patients: Determinants, pharmacist interventions and clinical outcomes-A prospective observational study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Enhancing Cancer Immunotherapy with Berberine and Its Loaded Nanoparticles: A Systematic Review.

Anti-cancer agents in medicinal chemistry·2026

Magnetic and Non-Magnetic Halloysite Nanotubes Functionalized with Folic Acid for the Targeted Delivery of [Pd(dipic)Cl].H2O: Cytotoxicity and Apoptosis Induction in Colon Cancer Cells.

Anti-cancer agents in medicinal chemistry·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us